Systemic Therapy of Incurable Gastroenteropancreatic Neuroendocrine Tumoursenglish
To make recommendations with respect to systemic therapy for the treatment of patients with incurable gastroenteropancreatic (GEP) neuroendocrine tumours (NETs).
Adults with a diagnosis of incurable GEP NETs.
Intended Guideline Users
Clinicians involved in the treatment of patients with GEP NETs.
Which of the anti-neoplastic systemic therapies (i.e., chemotherapy, SSAs and interferon α, and targeted therapies [i.e., sunitinib, everolimus, bevacizumab, pazopanib]) is the most effective in improving clinical outcomes (i.e., PFS, OS, ORR, median survival, symptom control, biomarker decreases, quality of life) while minimizing adverse effects (i.e., toxicity) in patients with incurable GEP NETs?